Using technology that is a cross between gene therapy and radiotherapy, Angiogene Inc. hopes to halt or prevent diseases characterized by excessive cell proliferation. Founded by interventional cardiologist Guy Leclerc, MD, the director of the Molecular Cardiology Laboratory at the Centre Hospitalier de L'Universite de Montreal , (CHUM) the company will focus on cardiovascular diseases, in particular restenosis, but the technology is applicable to cancer and other proliferative disorders.
In the US, every year approximately 500,000 patients undergo angioplasties to unblock clogged arteries, and all are candidates for anti-restenosis...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?